Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...
Latest milestone underscores accelerating regulatory momentum for the company’s lead investigational Helicon peptide, following FDA Fast Track Designation in desmoid tumors CAMBRIDGE, Mass., March 11, ...
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in ...
FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...
A long list of drug targets are deemed undruggable, beyond the reach of current drug discovery technologies. A few companies hope to soon cross the β-catenin transcription factor off that list.
Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by ...
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results